OIG Rejects Drug Company’s Proposed Cost-Assistance Program for Pricey Drug
- September 25, 2020
A pharmaceutical manufacturer’s proposal to provide cost-sharing assistance directly to Medicare beneficiaries who are prescribed either of two formulations of its drug could trigger sanctions under the Anti-Kickback Statute (AKS), according to an advisory opinion posted September 23.
ARTICLE TAGS
You must be logged in to access this content.